Showing results (61-70 of 157) with videos related to
Sort By:
Pageof 16
Nature Reviews. Clinical Oncology|November 11, 2025
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approachesJing Zhao, Wanting Xu, Fei Zhou, et al.Lung Cancer (Amsterdam, Netherlands)|July 27, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical expertsNancee Pronsati, Geoffrey Liu, Todd M Bauer, et al.Cancer Chemotherapy and Pharmacology|September 1, 2007
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacyBrigette Ma, Edwin P Hui, Ann King, et al.Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.European Journal of Cancer (Oxford, England : 1990)|June 24, 2014
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trialJames Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, et al.Future Oncology (London, England)|December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKITony Mok, Pasi A Jänne, Makoto Nishio, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2018
The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung CancerChee Khoon Lee, Sally Lord, Ian Marschner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancerRaymond P Abratt, Jung Sin Lee, Ji Youn Han, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.Pageof 16